News Releases

Keyword Search

Feb-22-2017
Oncternal Closes $18.4 Million Series B Financing
Dec-06-2016
Oncternal’s Pipeline Candidates Featured in Presentations at American Society of Hematology Meeting
Aug-30-2016
Oncternal Therapeutics Initiates Patient Dosing in Phase 1 Clinical Trial of TK216 in Ewing Sarcoma
Jul-13-2016
TK216 Receives Orphan Drug Designation for the Treatment of Ewing Sarcoma, a Rare Pediatric Cancer
Jun-20-2016
Oncternal Receives Fast Track Designation for TK216 in Relapsed or Refractory Ewing Sarcoma
Jun-01-2016
Oncternal Merges with Tokalas to Form Clinical-Stage Biotech Company w/ Promising Oncology Pipeline
Apr-12-2016
Oncternal Awarded Exclusive Worldwide License to ROR1 Antibody and Related Programs from UCSD